Trial Profile
A Phase II Open-Label Extension Study To Evaluate The Long-Term Safety And Efficacy Of Fenebrutinib In Patients Previously Enrolled In A Fenebrutinib Chronic Spontaneous Urticaria Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2020
Price :
$35
*
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Sponsors Genentech
- 02 Sep 2020 Status changed from completed to discontinued.
- 14 Feb 2020 Status changed from discontinued to completed.
- 22 Nov 2019 Status changed from recruiting to discontinued.